Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-13978
Dissanayake, S K; Olkhanud, P B; O'Connell, M P; Carter, A; French, A D; Camilli, T C; Emeche, C D; Hewitt, K J; Rosenthal, D T; Leotlela, P D; Wade, M S; Yang, S W; Brant, L; Nickoloff, B J; Messina, J L; Biragyn, A; Hoek, K S; Taub, D D; Longo, D L; Sondak, V K; Hewitt, S M; Weeraratna, A T (2008). Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Research, 68(24):10205-10214.
|PDF - Registered users only|
There are currently no effective therapies for metastatic melanoma and targeted immunotherapy results in the remission of only a very small percentage of tumors. In this study, we show that the noncanonical Wnt ligand, Wnt5A, can increase melanoma metastasis in vivo while down-regulating the expression of tumor-associated antigens important in eliciting CTL responses (e.g., MART-1, GP100, and tyrosinase). Melanosomal antigen expression is governed by MITF, PAX3, and SOX10 and is inhibited upon signal transducers and activators of transcription 3 (STAT3) activation, via decreases in PAX3 and subsequently MITF expression. Increasing Wnt5A in Wnt5A-low cells activated STAT3, and STAT3 was decreased upon Wnt5A knockdown. Downstream targets such as PAX3, MITF, and MART-1 were also affected by Wnt5A treatment or knockdown. Staining of a melanoma tissue array also highlighted the inverse relationship between MART-1 and Wnt5A expression. PKC activation by phorbol ester mimicked Wnt5A effects, and Wnt5A treatment in the presence of STAT3 or PKC inhibitors did not lower MART-1 levels. CTL activation studies showed that increases in Wnt5A correspond to decreased CTL activation and vice versa, suggesting that targeting Wnt5A before immunotherapy may lead to the enhancement of current targeted immunotherapy for patients with metastatic melanoma.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic|
|DDC:||610 Medicine & health|
|Deposited On:||26 Feb 2009 11:05|
|Last Modified:||27 Nov 2013 23:06|
|Publisher:||American Association for Cancer Research|
|Free access at:||Publisher DOI. An embargo period may apply.|
|Citations:||Web of Science®. Times cited: 36|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page